July 23, 2019
Aspen Japan said on July 22 that it will take over the Japanese marketing authorization for Bristol-Myers Squibb’s antiarrhythmic drug Sotacor (sotalol), effective September 30. This is the latest in a series of off-patent product successions by South Africa-based Aspen,...read more